2021
DOI: 10.3389/fimmu.2021.670827
|View full text |Cite
|
Sign up to set email alerts
|

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

Abstract: The development of immune checkpoint inhibitors (ICI) has dramatically changed the landscape of therapies for metastatic renal cell carcinoma. However, many patients do not benefit from such therapy and prognostic or predictive validated biomarker validated for ICI are still needed to better select and treat patient. Plasmatic soluble immune checkpoints have been described as potential immune biomarkers in hematological malignancies and solids tumors, then, we would like to explore the prognostic value of diff… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 18 publications
0
7
0
Order By: Relevance
“…Then, BTN3A1 could dynamically coordinate ab and gd T-cell-driven antitumor immunity to eliminate the malignant progression of ovarian cancer (32). Additionally, a few studies have revealed that BTN3A1 is a candidate prognostic biomarker for pancreatic adenocarcinoma, metastatic gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and renal cell carcinoma (33)(34)(35), and can effectively anticipate response to nivolumab therapy among patients with metastatic renal cell carcinoma (36). It has been reported that SLFN11, a cellular restriction factor, is closely related to tumor immune lymphocytes, immune checkpoint genes, chemokines, and immune-related signaling pathways in clear cell renal cell carcinoma (37), which is similar to our bioinformatics analysis.…”
Section: Discussionmentioning
confidence: 99%
“…Then, BTN3A1 could dynamically coordinate ab and gd T-cell-driven antitumor immunity to eliminate the malignant progression of ovarian cancer (32). Additionally, a few studies have revealed that BTN3A1 is a candidate prognostic biomarker for pancreatic adenocarcinoma, metastatic gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and renal cell carcinoma (33)(34)(35), and can effectively anticipate response to nivolumab therapy among patients with metastatic renal cell carcinoma (36). It has been reported that SLFN11, a cellular restriction factor, is closely related to tumor immune lymphocytes, immune checkpoint genes, chemokines, and immune-related signaling pathways in clear cell renal cell carcinoma (37), which is similar to our bioinformatics analysis.…”
Section: Discussionmentioning
confidence: 99%
“…Immune checkpoint inhibitors (ICIs) have become an indelible mark in the eld of cancer immunotherapy (43). Emilien Billon et al found that higher baseline plasma levels of BTN2A1 were signi cantly associated with shorter PFS in renal cell carcinoma (44). The PRDELSig score was positively correlated with the expression levels of immune checkpoint genes (BTN2A1, CD276, TNFSF4, TNFSF9).…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, Billon et al did not document any impact of the plasma sBTLA level on patient survival with metastatic RCC treated with the IC blockade. Thus, sBTLA has not been shown to be a good predictive biomarker for nivolumab therapy in metastatic RCC patients previously treated for metastatic RCC with TKI [ 113 ]. Similarly, Botticelli et al found that sLAG, while not sBTLA, can serve as a predictive biomarker in advanced HNCa patients treated with chemo- or immune-therapy [ 112 ].…”
Section: Sbtla and Cancermentioning
confidence: 99%